Glucagon in MODY (Maturity Onset Diabetes of the Young)
NCT ID: NCT03246828
Last Updated: 2022-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2017-07-03
2022-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea
NCT03081676
Impact of SGLT2 on Glucosuria in HNF1A-MODY
NCT05417646
Glucagon Modulation of Ghrelin Secretion
NCT00929812
Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)
NCT01342939
The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)
NCT04064203
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omission of gliclazide
Omission of gliclazide
Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Omission of gliclazide
Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently on gliclazide treatment
Exclusion Criteria
* Oral steroid treatment 30 days prior to the start or at any time during the study period.
* Known malignancy or any other condition or circumstance which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol.
* Felt to be unsuitable to participate in the study in the opinion of the Chief Investigator.
* Currently participating in a clinical trial involving an anti-diabetic medication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oxford University Hospitals NHS Trust
OTHER
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ioannis Spiliotis, MD
Role: PRINCIPAL_INVESTIGATOR
University of Oxford
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Unit, OCDEM, Churchill Hospital
Oxford, Oxfordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12538
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.